Multiscale Modelling of Nano-Drug Interactions Using Artificial Intelligence

machine learning

Nanomedicine is an emerging field with the potential to revolutionize disease treatment through targeted drug delivery using nanoparticles (NPs). The unique properties of nanoparticles, such as their small size, large surface area, and the ability to be customized for specific tasks, provide significant advantages in enhancing drug efficacy, bioavailability, and minimizing side effects. However, the interactions between nanoparticles and drugs are complex, requiring advanced methods to understand their behavior at multiple biological scales. The integration of multiscale modeling and artificial intelligence (AI) presents a promising approach to optimize nanoparticle-based drug delivery systems. Multiscale modeling combines computational techniques across various biological levels, from atomic interactions to tissue and organ responses, bridging the gap between nanoscale behaviors and macroscopic therapeutic outcomes. Molecular dynamics (MD) simulations provide detailed insights into the atomic-level interactions between nanoparticles and drugs, while cellular models predict nanoparticle uptake and drug release. By extending these models to simulate tissue behavior, factors such as circulation time and immune response can be incorporated. While molecular models alone are insufficient, multiscale approaches integrate these complex biological processes to predict therapeutic outcomes more accurately. AI, particularly machine learning (ML), enhances the predictive capabilities of these models by learning from large datasets that include nanoparticle characteristics, drug properties, and biological responses. ML algorithms can predict how changes in nanoparticle design parameters affect drug release profiles and therapeutic outcomes, while also identifying nonlinear relationships that traditional models struggle to capture. Additionally, AI-driven inverse modelling can optimize nanoparticle formulations, reducing experimental costs and time. Deep learning techniques, such as convolutional and recurrent neural networks, can automate the analysis of experimental data, uncovering hidden patterns in nano-drug interactions and continuously refining predictions. Hybrid models that combine AI with traditional mechanistic approaches offer a more robust understanding of nanoparticle behaviour in biological environments. Reinforcement learning (RL) enables autonomous exploration of nanoparticle design space, optimizing specific therapeutic objectives, such as targeting efficiency or drug release kinetics. Despite the promise of AI and multiscale modelling, challenges persist, including the need for high-quality datasets that capture the complexity of nanoparticle-drug interactions. As data collection standards improve and AI algorithms evolve, these tools will become increasingly essential in advancing the field of nanomedicine and optimizing drug delivery systems.

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.